Aura Biosciences (NASDAQ:AURA – Get Free Report) and VectivBio (NASDAQ:VECT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.
This is a summary of recent recommendations and price targets for Aura Biosciences and VectivBio, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Aura Biosciences presently has a consensus price target of $23.50, suggesting a potential upside of 139.06%. VectivBio has a consensus price target of $24.33, suggesting a potential upside of 44.41%. Given Aura Biosciences’ stronger consensus rating and higher possible upside, research analysts plainly believe Aura Biosciences is more favorable than VectivBio.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Aura Biosciences has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, VectivBio has a beta of 0.11, indicating that its share price is 89% less volatile than the S&P 500.
Valuation & Earnings
This table compares Aura Biosciences and VectivBio’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Aura Biosciences||N/A||N/A||-$58.76 million||($2.00)||-4.92|
|VectivBio||$27.34 million||20.97||-$93.74 million||N/A||N/A|
Aura Biosciences has higher earnings, but lower revenue than VectivBio.
Insider & Institutional Ownership
70.9% of Aura Biosciences shares are held by institutional investors. 5.9% of Aura Biosciences shares are held by insiders. Comparatively, 9.7% of VectivBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
About Aura Biosciences
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.
Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.